Keywords: بواسیزوماب; Angiogenesis; Bevacizumab; Regorafenib; VEGF; Ziv-aflibercept;
مقالات ISI بواسیزوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بواسیزوماب; IL-6; Angiogenesis; VEGF; STAT3; HIF-1α; Bevacizumab; Sunitinib; Siltuximab;
Keywords: بواسیزوماب; Poly(lactide-co-glycolide); Poly(ethylene glycol); Fluorescein isothiocyanate-dextran; Polyethyleneimine; Bevacizumab; Ranibizumab; Verteporfin (PubChem CID: 5362420); Rostaporfin (PubChem CID: 23725012); Methoxypoly(ethylene glycol)-poly(β-caprolactone);
Keywords: بواسیزوماب; Drug resistance; Re-challenge; Overcome resistance; Oxaliplatin; Irinotecan; Bevacizumab; 5-Fluorouracil; Cetuximab
Keywords: بواسیزوماب; Angiogenesis; Bevacizumab; Breast cancer; VEGF;
Keywords: بواسیزوماب; Vascular endothelial growth factor; Physiologic retinal vascular development (PRVD); Intravitreal neovascularization (IVNV); Bevacizumab; Angiogenesis; Oxygen-induced retinopathy (OIR);
Keywords: بواسیزوماب; Metastatic colorectal cancer; Irinotecan; Oxaliplatin; Cetuximab; Bevacizumab; Chemotherapy regimen sequencing; FOLFIRI; FOLFOX
Keywords: بواسیزوماب; Ovarian cancer; Bevacizumab; Relapse; Hypertension; Intestinal perforation;
Keywords: بواسیزوماب; Erlotinib; Bevacizumab; Non-squamous; Non-small cell lung cancer; First-line; Combination therapy;
Keywords: بواسیزوماب; Bevacizumab; ISG15 expression; Non-small-cell lung cancer; Refractory; Second-line therapy; Topotecan;
Keywords: بواسیزوماب; Pemetrexed; Cost effectiveness; Paclitaxel; Bevacizumab; Non-small cell lung cancer; Survival outcomes;
Keywords: بواسیزوماب; Renal cell carcinoma; Sequential therapy; Survival; Sunitinib; Sorafenib; Everolimus; Bevacizumab; Axitinib; Temsirolimus; Third-line;
Keywords: بواسیزوماب; Angiogenesis; Castration resistant prostate cancer; Vascular endothelial growth factor; Bevacizumab; Sunitinib; Cabozantinib;
Keywords: بواسیزوماب; Breast cancer; Adverse events; Trastuzumab; Pertuzumab; Lapatinib; Bevacizumab; Trastuzumab-emtansine; Everolimus; ABC; advanced breast cancer; QoL; quality of life; AE; adverse event; HER2; human epidermal growth factor receptor type 2; LVEF; left ventri
Keywords: بواسیزوماب; Colorectal cancer; Antiangiogenic therapy; Bevacizumab; Circulating biomarkers; Tissue biomarkers; Pharmacogenetic biomarkers;
Keywords: بواسیزوماب; Targeted therapy; Bevacizumab; Cetuximab; Rectal cancer; Neoadjuvant-treatment;
Keywords: بواسیزوماب; Cervical cancer; Recurrence; Chemotherapy; Platinum; Bevacizumab;
Keywords: بواسیزوماب; Bevacizumab; Surgery; Lung cancerLA-NSCLC NSCLC, locally advanced non-small cell carcinoma; Bev, bevacizumab; VEGF, vascular endothelial growth factor; CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography; CDDP, cisplatin; D
Keywords: بواسیزوماب; Bevacizumab; Hypertension; Chemotherapy
Keywords: بواسیزوماب; Aged; Colorectal neoplasms; Secondary; Molecular targeted therapy; Bevacizumab; Cohort studies
Keywords: بواسیزوماب; antiangiogenesis; bevacizumab; cervical cancer
Keywords: بواسیزوماب; Bevacizumab; Diabetic retinopathy; Macular edema; Sub-tenon’s injection
Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA⢠3200 biosensor
Keywords: بواسیزوماب; Immunotherapy; Monoclonal antibodies; Bevacizumab; Cetuximab; Immunoassay; KinExA;
A Proximity Extension Assay (PEA)-based method for quantification of bevacizumab
Keywords: بواسیزوماب; Proximity Extension Assay (PEA); Bevacizumab; Anti-VEGF; Systemic concentration; Intravitreal administration;
Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
Keywords: بواسیزوماب; Cervical cancer; Metronomic chemotherapy; Bevacizumab;
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study
Keywords: بواسیزوماب; Bevacizumab; Clinical trial; FOLFIRI; Gastroenteropancreatic; Neuroendocrine carcinoma;
Intravitreal bevacizumab as rescue therapy following treatment failure with laser photocoagulation in retinopathy of prematurity
Keywords: بواسیزوماب; Bevacizumab; Retinopathy of prematurity; Photocoagulation; Rescue therapy; Treatment failure;
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404
Keywords: بواسیزوماب; Non-small-cell lung cancer; EGFR; Bevacizumab; Afatinib; EGFR-TKI; Phase Ib;
Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in Patients With Recurrent Malignant Gliomas
Keywords: بواسیزوماب; Stereotactic radiosurgery; Glioma; Bevacizumab; Vascular endothelial growth factor-A;
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer
Keywords: بواسیزوماب; Osimertinib; EGFR T790M; Resistance mutation; Docetaxel; Bevacizumab; Non-small-cell lung cancer;
Role of bevacizumab in uterine leiomyosarcoma
Keywords: بواسیزوماب; Adjuvant; Bevacizumab; Chemotherapy; Survival; Uterine leiomyosarcoma;
Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance)
Keywords: بواسیزوماب; Advanced cancer; Advanced colon cancer; Advanced rectal cancer; Older adult; Advanced colorectal cancer; Clinical trial; Elderly; Oxaliplatin; Bevacizumab;
Simple and ultra-fast recognition and quantitation of compounded monoclonal antibodies: Application to flow injection analysis combined to UV spectroscopy and matching method
Keywords: بواسیزوماب; Bvz; bevacizumab; CS; control standard; ifx; infliximab; PCA; principal component analysis; QC; quality control; rtx; rituximab; SEN; sensitivity; SPE; specificity; trz; trastuzumab; Monoclonal antibody; Qualitative control; Quantitative control; Second d
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
Keywords: بواسیزوماب; Endometrial cancer; Paclitaxel; Carboplatin; Bevacizumab; Temsirolimus; Ixabepilone;
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂ and COIN-B trials in the ARCAD databa
Keywords: بواسیزوماب; Left-sided colon cancer; Rectal cancer; Outcomes; Bevacizumab; Cetuximab;
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer
Keywords: بواسیزوماب; Geriatric assessment; Colon cancer; Predictive factors; Bevacizumab; Elderly;
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
Keywords: بواسیزوماب; Overweight; Prognostic factor; Pooled analysis; Colorectal cancer; Bevacizumab;
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
Keywords: بواسیزوماب; Colorectal cancer; Prognostic factors; Primary tumour location; RAS mutation; BRAF mutation; Bevacizumab; Overall survival; First-line therapy;
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3
Keywords: بواسیزوماب; Metastatic colorectal cancer; Resection; Conversion therapy; Cetuximab; Bevacizumab; Surgery;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)
Keywords: بواسیزوماب; Aflibercept; Bevacizumab; Cetuximab; Infection; Pertuzumab; Small-molecule inhibitors; Trastuzumab; Tyrosine kinase inhibitors; VEGF-targeted agents;
Recurrent Severe Hypoinsulinemic Hypoglycemia Responsive to Temozolomide and Bevacizumab in a Patient With Doege-Potter Syndrome
Keywords: بواسیزوماب; Doege-Potter syndrome; Hypoglycemia; Temozolomide; Bevacizumab;
Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF
Keywords: بواسیزوماب; Anti-VEGF; Bevacizumab; C-reactive protein; Diabetic macular edema; Inflammatory biomarkers;
The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review
Keywords: بواسیزوماب; Bevacizumab; Cervical cancer; Endometrial cancer; Ovarian cancer;
Diffusely Infiltrating Cerebellar Anaplastic Astrocytoma Effectively Controlled with Bevacizumab: Case Report and Literature Review
Keywords: بواسیزوماب; Bevacizumab; Cerebellar glioma; Diffuse infiltration; Gd; Gadolinium; MRI; Magnetic resonance imaging;
Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy
Keywords: بواسیزوماب; Recurrent glioma; Salvage therapy; Health related quality of life; Bevacizumab; Temozolomide;
Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria
Keywords: بواسیزوماب; Phagocytosis; Latex beads; Bevacizumab; Ranibizumab; Aflibercept; Anti-VEGF; Cybrids; Retinal pigment epithelium; Mitochondria; Age-related macular degeneration;
Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium
Keywords: بواسیزوماب; Bevacizumab; Ranibizumab; Aflibercept; Rituximab; RPE; Senescence; Aging;
Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer
Keywords: بواسیزوماب; Angiogenesis; Bevacizumab; Cancer; Photodynamic therapy;
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Keywords: بواسیزوماب; Bevacizumab; Colorectal cancer; FOLFOXIRI; UGT1A1;
Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer
Keywords: بواسیزوماب; Ovarian cancer; Dose-dense chemotherapy; Bevacizumab; Anti-VEGF;